

Cycloset® (bromocriptine mesylate) tablets
Effective 04/17/19

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Cycloset® (bromocriptine mesylate) is a dopamine receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Coverage Guidelines

Authorization may be granted when ALL the following criteria are met:

1. Member has a diagnosis of Type 2 diabetes mellitus
2. Member has experienced an inadequate response or intolerance to metformin or a metformin-containing product (unless metformin use is medically contraindicated).
3. Member has experienced an inadequate response or intolerance to at least ONE agent from TWO of the following categories:
 - a. TZD's (e.g., pioglitazone, rosiglitazone, etc.)
 - b. DPP-4 inhibitors (e.g., sitagliptin, saxagliptin, linagliptin, alogliptin, etc.)
 - c. Incretin mimetics (e.g., exenatide, liraglutide, albiglutide, etc.)
 - d. Sodium-glucose Co-transporter-2 (SGLT-2) inhibitor (e.g., canagliflozin, dapagliflozin, etc.)
 - e. Insulin (with caution)
 - f. Colesevelam

Continuation of Therapy

Reauthorization requires physician documentation of improvement of member's condition.

Limitations

1. Approvals will be for 36 months.
2. The following quantity limits apply:

Cycloset	180 tablets per 30 days
----------	-------------------------

References

1. Cycloset (bromocriptine mesylate) tablets [prescribing information]. Tiverton, RI: VeroScience; February 2017
2. The American Diabetes Association. Standards of medical care in diabetes – 2014. *Diabetes Care*. 2014;37(supp 1):S14-80.
3. Rodboard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an AACE/ACE Consensus Panel on Type 2 Diabetes Mellitus: An algorithm for glycemic control. *Endocr Pract*. 2009 Sep;15(6):540-59.
4. ADA and the European Association for the Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care*. 2009 Jan;32(1):193-203.
5. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract*. 2011 Mar-Apr;17 Suppl 2:1-53.
6. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P, et al. Oral Pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2012;156:218-31.
7. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE Comprehensive Diabetes Management Algorithm: 2013. *Endocrine Practice*. 2013 Mar/Apr;19(2):327-336.
8. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015. *Endocrine Practice*. 2015;21(Supp 1)
9. AACE/ACE Comprehensive Diabetes Management Algorithm 2015. [published ahead of print]. DOI: 10.4158/P15693.CS. Available at: www.aace.com/publications/algorithm

Review History

06/27/11 – Reviewed
 08/01/11 – Effective
 06/25/12 – Reviewed
 12/01/12 – Updated (RxAuth)
 06/24/13 – Reviewed
 06/23/14 – Reviewed
 06/22/16 – Reviewed
 06/26/17 – Reviewed
 04/17/19 – Reviewed in P&T Meeting

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.